# Ocelot Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ocelot-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.ocelotbio.com
- Total disclosed funding: $36M
- Latest round: Series A (Apr 15, 2021)
- Investors on record: 3

## About

Based in California, US, and founded in 2020 by Geoff Harris, Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for patients with liver diseases. In March 2022, Ocelot Bio, Inc. raised USD 36 million in a Series A funding co-led by RA Capital Venrock and Vivo Capital. As of March 2022, Katherine Vega Stultz is the President and CEO of Ocelot Bio, Inc.

Ocelot Bio’s product line includes OCE-205, a therapeutic peptide that targets complications of ESLD-induced portal hypertension for patients with liver diseases like HRS-AKI. OCE-205 is under phase 2 clinical trial to evaluate its effectiveness in the treatment of HRS-AKI, a serious and life-threatening consequence of ESLD, that leads to acute renal failure and often death.

The company plans to use its proceeds from March 2022 funding to accelerate IND clearance of its lead product and support the advancement of OCE-205 into other indications like ascites.

## Funding rounds

- Series A, Apr 15, 2021, $36M — Venrock, Vivo Capital, RA Capital Management

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A